^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
EU101
i
Other names: EU101, EU-101, NOV1801, HOT-1030
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Eutilex, National OncoVenture, Zhejiang Huahai Pharma
Drug class:
CD137 agonist
Related drugs:
2ms
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=110, Recruiting, Eutilex | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Sep 2025
Trial completion date • Trial primary completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
MSI-H/dMMR • RAS mutation
|
EU101
over2years
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=96, Recruiting, Eutilex | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
MSI-H/dMMR
|
EU101
almost3years
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=96, Not yet recruiting, Eutilex
Clinical • New P1/2 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
MSI-H/dMMR
|
EU101
Share via
